Ifosfamide-based combination chemotherapy in advanced non-small cell lung cancer: two phase I studies
| Autor: | P C, Hoffman, G A, Masters, L C, Drinkard, S A, Krauss, B L, Samuels, H M, Golomb, E E, Vokes |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Adult
Male Lung Neoplasms Neutropenia Paclitaxel Remission Induction Vinorelbine Drug Tolerance Middle Aged Vinblastine Antineoplastic Agents Phytogenic Survival Rate Carcinoma Non-Small-Cell Lung Antineoplastic Combined Chemotherapy Protocols Granulocyte Colony-Stimulating Factor Humans Female Ifosfamide Antineoplastic Agents Alkylating Aged Expectorants Mesna Neoplasm Staging |
| Zdroj: | Seminars in oncology. 23(3 Suppl 6) |
| ISSN: | 0093-7754 |
| Popis: | Two studies were performed to determine the maximum tolerated dose (MTD) of paclitaxel and vinorelbine, respectively, in combination with a fixed dose of ifosfamide in previously untreated patients with stage IIIB or IV non-small cell lung cancer. Response rate and survival were also assessed. Both regimens were given with mesna and granulocyte colony-stimulating factor support. The maximum tolerated dose of paclitaxel in combination with 1.6 g/m2/d X 3 ifosfamide was 300 mg/m2, and the recommended dose for phase II study is 250 mg/m2. Among 31 patients treated with ifosfamide/paclitaxel, there were seven partial responses; additionally, 10 patients had either minor regression or stable disease. The maximum tolerated dose of vinorelbine in combination with 1.6 g/m2/d X 3 ifosfamide was 35 mg/m2/d X 3, and the recommended dose for phase II study is 30 mg/m2/d X 3. Among 42 patients treated with ifosfamide/vinorelbine, responses have been encouraging, and final analysis is pending. The dose-limiting toxicity for both regimens was neutropenia. These findings indicate that ifosfamide-containing combination chemotherapy regimens have activity in advanced non-small cell lung cancer and are well tolerated when administered with granulocyte colony-stimulating factor. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|